Key result
Novel lipid-targeting therapies offer potential synergies with established agents to treat atherosclerosis.
Answers are grounded in this paper and cite their sources.
Lipid-lowering is established as proven intervention to reduce atherosclerosis and its complications. This article summarises novel developments in the lipid-altering therapies under development. It also discusses other therapeutic targets, such as squalene synthase, microsomal transfer protein, acyl-cholesterol acyl transferase, cholesterol ester transfer protein, peroxosimal proliferator-activating receptors and lipoprotein (a), for which compounds have been developed and have at least reached trials in animal models. Lipid-altering drugs are likely to prove a fast-developing area for novel treatments, as possible synergies exist between new and established compounds for the treatment of atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Anthony S. Wierzbicki (2004) conducted a review in Atherosclerosis. Novel lipid-altering therapies vs. Established lipid-lowering compounds was evaluated. Novel lipid-altering therapies targeting enzymes like squalene synthase, MTP, ACAT, CETP, PPARs, and Lp(a) may offer future synergies with established drugs to treat atherosclerosis.
Synapse has enriched 10 related papers. Consider them for comparative context: